Fate Therapeutics (FATE) Long-Term Deferred Tax (2024 - 2025)
Fate Therapeutics (FATE) reported Long-Term Deferred Tax of $2.3 million for Q4 2025, up 100.35% on a YoY basis from $1.1 million in Q4 2024, and up 100.35% quarter-over-quarter from $1.1 million in Q4 2024.
Fate Therapeutics (FATE) Long-Term Deferred Tax (2024 - 2025) Analysis & Trends
Fate Therapeutics has reported Long-Term Deferred Tax for 2 years, with the latest figure at $2.3 million in Q4 2025.
- For the quarter ending Q4 2025, Long-Term Deferred Tax rose 100.35% year-over-year to $2.3 million; the trailing twelve-month figure through Dec 2025 stood at $2.3 million (up 100.35% YoY), and the FY2025 full-year result was $2.3 million, up 100.35% from the prior year.
- Long-Term Deferred Tax for Q4 2025 stood at $2.3 million, up from $1.1 million in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $2.3 million in Q4 2025, with the low at $1.1 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Fate Therapeutics | 250.86 Mn | 250.86 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 1.15 Mn |